CL2014002547A1 - Formulacion vesicular en crema, locion, ungüento, gel, solucion, aerosol, laca o solucion filmogena, que comprende uno o mas fosfolipidos o sulfolipidos y uno o mas surfactantes; metodo para tratar la rosacea; y su uso para el tratamiento de la rosacea. - Google Patents
Formulacion vesicular en crema, locion, ungüento, gel, solucion, aerosol, laca o solucion filmogena, que comprende uno o mas fosfolipidos o sulfolipidos y uno o mas surfactantes; metodo para tratar la rosacea; y su uso para el tratamiento de la rosacea.Info
- Publication number
- CL2014002547A1 CL2014002547A1 CL2014002547A CL2014002547A CL2014002547A1 CL 2014002547 A1 CL2014002547 A1 CL 2014002547A1 CL 2014002547 A CL2014002547 A CL 2014002547A CL 2014002547 A CL2014002547 A CL 2014002547A CL 2014002547 A1 CL2014002547 A1 CL 2014002547A1
- Authority
- CL
- Chile
- Prior art keywords
- solution
- rosacea
- sulpholipids
- lacquer
- phospholipids
- Prior art date
Links
- 201000004700 rosacea Diseases 0.000 title 2
- 241001303601 Rosacea Species 0.000 title 1
- 239000006071 cream Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000499 gel Substances 0.000 title 1
- 239000004922 lacquer Substances 0.000 title 1
- 239000006210 lotion Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002674 ointment Substances 0.000 title 1
- 150000003904 phospholipids Chemical class 0.000 title 1
- 239000000243 solution Substances 0.000 title 1
- 239000007921 spray Substances 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1205642.0A GB201205642D0 (en) | 2012-03-29 | 2012-03-29 | Vesicular formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002547A1 true CL2014002547A1 (es) | 2015-03-27 |
Family
ID=46159988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002547A CL2014002547A1 (es) | 2012-03-29 | 2014-09-25 | Formulacion vesicular en crema, locion, ungüento, gel, solucion, aerosol, laca o solucion filmogena, que comprende uno o mas fosfolipidos o sulfolipidos y uno o mas surfactantes; metodo para tratar la rosacea; y su uso para el tratamiento de la rosacea. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9555051B2 (enExample) |
| EP (1) | EP2830630A1 (enExample) |
| JP (1) | JP2015511618A (enExample) |
| KR (1) | KR20150004798A (enExample) |
| CN (1) | CN104349782A (enExample) |
| AU (1) | AU2013241701A1 (enExample) |
| BR (1) | BR112014024033A8 (enExample) |
| CA (1) | CA2867749A1 (enExample) |
| CL (1) | CL2014002547A1 (enExample) |
| CO (1) | CO7121334A2 (enExample) |
| EA (1) | EA038899B1 (enExample) |
| GB (2) | GB201205642D0 (enExample) |
| IL (1) | IL234747A0 (enExample) |
| IN (1) | IN2014DN07913A (enExample) |
| MX (1) | MX2014011516A (enExample) |
| NZ (1) | NZ700472A (enExample) |
| PH (1) | PH12014502065A1 (enExample) |
| SG (1) | SG11201406144TA (enExample) |
| WO (1) | WO2013144289A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012500360A1 (en) | 2009-08-21 | 2019-07-10 | Targeted Delivery Tech Limited | Vesicular formulations |
| SG11201705155SA (en) * | 2014-12-23 | 2017-07-28 | Camurus Ab | Controlled-release formulations |
| PT3316857T (pt) | 2015-06-30 | 2021-11-03 | Sequessome Tech Holdings Limited | Composições multifásicas |
| WO2019055880A2 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | METHOD OF ADMINISTRATION AND TREATMENT |
| WO2022180199A1 (en) * | 2021-02-25 | 2022-09-01 | Exinov | Emulsion for use in the treatment of rosacea |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60136511A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 高尿酸血症治療剤 |
| WO1987001938A1 (en) | 1985-09-27 | 1987-04-09 | The Regents Of The University Of California | Liposome transdermal drug delivery system |
| JPS6295134A (ja) | 1985-10-21 | 1987-05-01 | Nippon Saafuakutanto Kogyo Kk | リポソ−ムの製造法 |
| US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| US5498607A (en) | 1990-07-30 | 1996-03-12 | University Of Miami | Treatment for hypercholesterolemia |
| CA2067754C (en) | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| ATE158175T1 (de) | 1992-07-08 | 1997-10-15 | Dianorm G Maierhofer Gmbh | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels |
| FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
| DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| FR2767691B1 (fr) | 1997-08-27 | 2000-02-18 | Oreal | Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire |
| TR200001393T2 (tr) * | 1997-11-19 | 2000-10-23 | Schering Aktiengesellschaft | Azelain asitli terkip. |
| US6165997A (en) | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
| MXPA01002149A (es) | 1998-09-01 | 2003-03-27 | Idea Ag | Transporte electricamente controlado de penetrantes cargados a traves de barreras. |
| AU770803B2 (en) | 1998-12-23 | 2004-03-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
| PT1031346E (pt) | 1999-01-27 | 2002-09-30 | Idea Ag | Vacinacao nao invasiva atraves da pele |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| MXPA02000053A (es) | 1999-07-05 | 2003-07-21 | Idea Ag | Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables. |
| US6248728B1 (en) | 2000-03-10 | 2001-06-19 | Kansas State University Research Foundation | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol |
| US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
| DK1272161T3 (da) | 2000-04-12 | 2008-05-19 | Liplasome Pharma As | Lipid-baserede system til afgivelse af lægemidler mod parasitiske infektioner |
| TWI281407B (en) | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| EP1230917A1 (de) | 2001-02-08 | 2002-08-14 | Vectron Therapeutics AG | Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung |
| TNSN03127A1 (fr) | 2001-05-31 | 2005-12-23 | Pharmacia Corp | Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique |
| WO2003000190A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| CA2368656A1 (en) | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| NZ534377A (en) | 2002-03-13 | 2008-04-30 | Collagenex Pharm Inc | Water-based topical delivery system consisting of cholesterol, fatty acids water and a phospholipid/ceramide portion. |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| ES2298566T3 (es) | 2002-10-11 | 2008-05-16 | Idea Ag | Agregado con deformabilidad incrementada, que comprende por lo menos tres componentes anfipaticos, para un transporte mejorado a traves de barreras semipermeables y para la aplicacion de farmacos no invasiva in vivo, especialmente a traves de la piel. |
| JP2004131432A (ja) | 2002-10-11 | 2004-04-30 | Kumamoto Technology & Industry Foundation | 悪性腫瘍抑制剤 |
| CA2524478A1 (en) | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
| KR20060037369A (ko) | 2003-07-21 | 2006-05-03 | 바소겐 아일랜드 리미티드 | 급성 염증 상태의 치료를 위한 포스페이트 글리세롤 기를함유하는 리포솜 |
| JP2005179313A (ja) * | 2003-12-24 | 2005-07-07 | Shu Uemura:Kk | 皮膚化粧料用基剤の製造方法および皮膚化粧料 |
| US7476432B2 (en) | 2004-05-28 | 2009-01-13 | Tecton Products | Phosphorescent pultrusion |
| EP1811961A2 (en) | 2004-11-12 | 2007-08-01 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
| WO2006086992A2 (en) | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| US20070042008A1 (en) | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
| NZ565590A (en) | 2005-08-29 | 2010-07-30 | Sepsicure L L C | Use of a protein free composition comprising cholinic acid and a phosphosphlipid for the treatment or prevention of conditions caused by gram-positive bacteria |
| JP2009520824A (ja) | 2005-12-20 | 2009-05-28 | セネストラ エルエルシー | オメガ３脂肪酸製剤 |
| JP5009547B2 (ja) | 2006-03-31 | 2012-08-22 | 株式会社コーセー | 顔料とリポソームを含む化粧料 |
| US7544375B1 (en) | 2006-06-12 | 2009-06-09 | Swiss Skin Repair, Inc. | Composition |
| CA2664944C (en) | 2006-09-28 | 2016-06-14 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
| JP4732307B2 (ja) | 2006-11-20 | 2011-07-27 | 株式会社アンズコーポレーション | ナノエマルション及びそれを配合した化粧料 |
| US20100130611A1 (en) | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
| EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
| ITVR20080006A1 (it) | 2008-01-23 | 2009-07-24 | David Ceretta | Apparato per la realizzazione di elementi d'impasto |
| ES2335636B1 (es) | 2008-02-29 | 2011-05-11 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica de micelas mixtas. |
| JP2009256331A (ja) | 2008-03-25 | 2009-11-05 | Nagase Chemtex Corp | 高尿酸血症、又は痛風の予防、改善、又は治療剤 |
| US20100105139A1 (en) | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| MX2011008204A (es) | 2009-02-05 | 2011-12-06 | Targeted Delivery Technologies Ltd | Metodos para reducir la proliferacion y viabilidad de los agentes microbianos. |
| JP2012528846A (ja) | 2009-06-03 | 2012-11-15 | マヨ、ジョン、チャールズ | 深部組織の痛みを治療するための製剤 |
| PH12012500360A1 (en) | 2009-08-21 | 2019-07-10 | Targeted Delivery Tech Limited | Vesicular formulations |
| EP2382994A1 (en) | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
| WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| US20120045405A1 (en) | 2010-08-18 | 2012-02-23 | Gilman Miles E | Under eye cream |
| GB201206486D0 (en) | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| GB201208384D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
| GB201208409D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, kits and uses |
| JP2016529242A (ja) | 2013-07-31 | 2016-09-23 | シクエスサム テクノロジー ホールディングス リミテッド | ベシクル |
-
2012
- 2012-03-29 GB GBGB1205642.0A patent/GB201205642D0/en not_active Ceased
-
2013
- 2013-03-28 JP JP2015502351A patent/JP2015511618A/ja active Pending
- 2013-03-28 WO PCT/EP2013/056694 patent/WO2013144289A1/en not_active Ceased
- 2013-03-28 KR KR1020147027498A patent/KR20150004798A/ko not_active Withdrawn
- 2013-03-28 SG SG11201406144TA patent/SG11201406144TA/en unknown
- 2013-03-28 MX MX2014011516A patent/MX2014011516A/es unknown
- 2013-03-28 CA CA2867749A patent/CA2867749A1/en not_active Abandoned
- 2013-03-28 NZ NZ700472A patent/NZ700472A/en not_active IP Right Cessation
- 2013-03-28 CN CN201380027033.9A patent/CN104349782A/zh active Pending
- 2013-03-28 GB GB1419075.5A patent/GB2515440B/en not_active Expired - Fee Related
- 2013-03-28 AU AU2013241701A patent/AU2013241701A1/en not_active Abandoned
- 2013-03-28 US US14/388,469 patent/US9555051B2/en not_active Expired - Fee Related
- 2013-03-28 EP EP13712801.3A patent/EP2830630A1/en not_active Ceased
- 2013-03-28 EA EA201491581A patent/EA038899B1/ru unknown
- 2013-03-28 BR BR112014024033A patent/BR112014024033A8/pt not_active IP Right Cessation
- 2013-03-28 IN IN7913DEN2014 patent/IN2014DN07913A/en unknown
-
2014
- 2014-09-17 PH PH12014502065A patent/PH12014502065A1/en unknown
- 2014-09-18 IL IL234747A patent/IL234747A0/en unknown
- 2014-09-25 CL CL2014002547A patent/CL2014002547A1/es unknown
- 2014-10-28 CO CO14238690A patent/CO7121334A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150004798A (ko) | 2015-01-13 |
| NZ700472A (en) | 2016-02-26 |
| CA2867749A1 (en) | 2013-10-03 |
| US9555051B2 (en) | 2017-01-31 |
| GB201419075D0 (en) | 2014-12-10 |
| GB201205642D0 (en) | 2012-05-16 |
| EA201491581A1 (ru) | 2015-02-27 |
| JP2015511618A (ja) | 2015-04-20 |
| IL234747A0 (en) | 2014-11-30 |
| WO2013144289A1 (en) | 2013-10-03 |
| PH12014502065A1 (en) | 2014-12-10 |
| GB2515440B (en) | 2017-02-08 |
| CN104349782A (zh) | 2015-02-11 |
| GB2515440A (en) | 2014-12-24 |
| CO7121334A2 (es) | 2014-11-20 |
| BR112014024033A2 (enExample) | 2017-06-20 |
| IN2014DN07913A (enExample) | 2015-04-24 |
| SG11201406144TA (en) | 2014-10-30 |
| AU2013241701A1 (en) | 2014-10-16 |
| EP2830630A1 (en) | 2015-02-04 |
| BR112014024033A8 (pt) | 2017-07-25 |
| EA038899B1 (ru) | 2021-11-03 |
| US20150057249A1 (en) | 2015-02-26 |
| MX2014011516A (es) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013015498A2 (pt) | formulação localizada tópica, uso da formulação, e, método para tratamento ou profilaxia de infestação de parasita de um animal | |
| CL2013002673A1 (es) | Composicion que comprende un polipéptido aislado con actividad inhibidor de nav1.3 y nav1.7; composicion farmacéutica que comprende la composicion antes dicha; metodo para tratar dolor. | |
| GT201500105A (es) | Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso | |
| HRP20181598T1 (hr) | Uporaba i pripravci za liječenje hidradenitis suppurativa (hs) | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| HRP20181364T8 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
| IL239923A0 (en) | Solid solution compositions and use in cardiovascular disease | |
| CL2014002326A1 (es) | Combinacion que comprende benzodioxanos y uno o mas agentes activos y su uso en el tratamiento de enfermedades tales como ateroesclerosis e infarto al miocardio. | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| PT2848097T (pt) | Dispositivo para o tratamento de plasma de superfícies humanas, animais ou de plantas, em particular da pele ou de áreas de membrana mucosa | |
| BR112015010772A2 (pt) | composição de enxágue tópica, uso de uma composição e método para tratar ou melhorar a pele de um indivíduo contra a acne | |
| CL2015000966A1 (es) | Combinaciones de compuestos activos que comprenden derivados de carboxamida y un agente de control biológico; composiciones que las comprenden; método de control de hongos fitopatógenos en cultivos que las utiliza; y uso de las combinaciones y composiciones. | |
| CL2014002348A1 (es) | Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado. | |
| BR112015002706A2 (pt) | niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| CL2015000254A1 (es) | Vesículas que comprenden factor de crecimiento epidermico (egf); proceso de preparación; composición farmacéutica que las comprende; y uso para tratar heridas complejas . | |
| BR112015014885A2 (pt) | combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos. | |
| CL2014002547A1 (es) | Formulacion vesicular en crema, locion, ungüento, gel, solucion, aerosol, laca o solucion filmogena, que comprende uno o mas fosfolipidos o sulfolipidos y uno o mas surfactantes; metodo para tratar la rosacea; y su uso para el tratamiento de la rosacea. | |
| IT1405793B1 (it) | Molecola di u1snrna umano modificato, gene codificante per la molecola di u1snrna umano modificato, vettore di espressione includente il gene, e loro uso in terapia genica | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
| BR112014030553A2 (pt) | uso cosmético, como agente para prevenir e/ou tratar um defeito estético na pele e/ou seus apêndices, método relacionado, composto, e composição dermatológica | |
| CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. | |
| BR112013017953A2 (pt) | Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora | |
| WO2013060707A3 (de) | Kosmetische mittel enthaltend oxytocin und riechstoffe |